MedPath

A Pilot Study of the Effects of Botulinum Toxin in the Treatment of Provoked Vestibulodynia

Phase 3
Completed
Conditions
Vestibulodynia
Interventions
Other: Saline solution
Other: Indexes
Registration Number
NCT02858219
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
Brief Summary

The main objective of this study is to compare the efficacy of botulinum toxin injections on vestibulodynia pain compared to a group treated with a placebo.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
60
Inclusion Criteria
  • Subject refractory to conventional treatments (tricyclic antidepressants and benzodiazepines at analgesic doses, biofeedback physical therapy)
  • Negative screening test results
  • Notified associated factors
  • Menopause, surgically sterilized women or women using effective contraceptive method
  • Good understanding and predictable adherence to the protocol
  • beneficiary/affiliated to French social security/social healthcare
  • signed Informed Consent Form
Exclusion Criteria
  • Predictable poor adherence
  • Pregnant or breastfeeding women
  • Myasthenia
  • Treatment with aminoglycosides
  • Major mental disorders
  • Underlying etiology
  • Vulnerable subjects (particularly adults under guardianship)
  • Any reason deemed relevant by the investigator
  • Current or former (in the last 3 months) participation to another clinical trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Botulinum toxinIndexesInjection of 50 units (50U) botulinum toxin type A (powder), reconstituted in 1 mL physiologic saline solution in each perineal muscle (100 units in total). First injection at day 1 and. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale).
Saline solutionSaline solutionInjection of 1 mL physiologic saline solution in each perineal muscle. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale).
Saline solutionIndexesInjection of 1 mL physiologic saline solution in each perineal muscle. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale).
Botulinum toxinBotulinum Toxin Type AInjection of 50 units (50U) botulinum toxin type A (powder), reconstituted in 1 mL physiologic saline solution in each perineal muscle (100 units in total). First injection at day 1 and. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale).
Primary Outcome Measures
NameTimeMethod
Pain improvement3 months

Significant improvement of pain on contact in the treated group, compared to placebo group, measured with Visual Analogic Scale

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

CHU Besançon

🇫🇷

Besançon, France

Hôpital Tenon

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath